ArticleCancers2019

The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax.

Chiara Tarantelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.